Axsome Therapeutics (AXSM)
(Real Time Quote from BATS)
$73.84 USD
+2.13 (2.97%)
Updated Apr 29, 2024 03:02 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
AXSM 73.84 +2.13(2.97%)
Will AXSM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AXSM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AXSM
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
AXSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study
Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal
Why Is Axsome (AXSM) Down 4% Since Last Earnings Report?
Other News for AXSM
AXSM Crosses Above Key Moving Average Level
Axsome Therapeutics stock rises on upgrade to Overweight at Morgan Stanley
Buy Rating on Axsome Therapeutics Amidst Strong Auvelity Performance and Positive Revenue Prospects
Axsome Therapeutics just upgraded at Morgan Stanley, here's why
Buy Rating Affirmed for Axsome Therapeutics on Robust Product Pipeline and Market Growth Potential